Where Global Innovation
and Capital Meet
Sectors Consumer University Energy Financial Healthcare Industrial IT Media Services Telecoms Transport The Art of CVC Startups

Page 194

DispatchHealth posts series C details

The home care provider has closed a round led by Optum Ventures and backed by Humana and Echo Health Ventures at approximately $136m.

Jun 24, 2020

Repare rounds off $253m initial public offering

Celgene Switzerland and BMS-backed precision cancer drug developer Repare Therapeutics added $33m to its IPO after its shares rose 65% post-offering.

Jun 24, 2020

Foldax packs up $20m

MemorialCare Innovation Fund contributed to a series D round that brought the heart valve technology developer's overall funding to more than $36m.

Jun 23, 2020

Invitae to inhale ArcherDX in $1.4bn deal

The Qiagen-founded precision cancer technology provider agreed to an acquisition by Invitae sized at at least $325m in cash and shares currently valued at about $820m.

Jun 23, 2020

Genetron jumps to public markets in $256m IPO

Vcanbio scored an exit as the precision cancer treatment and diagnostics developer went public in an upsized offering priced well above its range.

Jun 23, 2020

Poseida points the way to $115m IPO

Novartis is the second largest investor in the gene therapy developer, which has filed to go public less than a year after closing a $150m round.

Jun 23, 2020

Cedar sees its way to $102m

The series C round consisted of $77m in equity funding and $25m in venture debt, with Kaiser Permanente among the participants.

Jun 23, 2020

Surrozen scurries to $50m series C

Hartford Healthcare returned for a $50m series C round that will support the Stanford spinout in advancing potential treatments for severe liver and inflammatory bowel diseases.

Jun 23, 2020

Big Health to grow with $39m

Kaiser Permanente Ventures and Samsung Next invested in the digital mental health treatment developer through a series B round that will fund product development and commercialisation.

Jun 23, 2020

Nan Fund enters Engrail in $32m round

Engrail Therapeutics has completed a series A round led by Nan Fung Life Sciences as it targets a validated mechanism-based approach to nervous system treatments.

Jun 23, 2020

© 2024 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here